Lilly's Weight Loss Drugs Soar, But Stock's Price is Too High

Eli Lillys weight loss drugs, Mounjaro and Zepbound, are soaring, but their stock is overvalued at a P/E of 34. Novo Nordisk is making a comeback with a new GLP-one drug, boasting a solid dividend yield and raised guidance. Pfizer is lagging, but their high dividend yield and potential turnaround make them an attractive option. Analysts suggest investors might find better value in Novo and Pfizer, balancing growth with dividends in this competitive market. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/92d47b9ac823faa9